SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
SEC Accession No. 0001213900-23-068745
Filing Date
2023-08-18
Accepted
2023-08-18 10:07:35
Documents
35
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 TO FORM 6-K ea183829-6ka2_biondvax.htm   iXBRL 6-K/A 19541
2 UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 202 ea183829ex99-1_biondvax.htm   iXBRL EX-99.1 442693
  Complete submission text file 0001213900-23-068745.txt   2229089

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE bvxv-20230630.xsd EX-101.SCH 31286
4 XBRL CALCULATION FILE bvxv-20230630_cal.xml EX-101.CAL 23199
5 XBRL DEFINITION FILE bvxv-20230630_def.xml EX-101.DEF 102863
6 XBRL LABEL FILE bvxv-20230630_lab.xml EX-101.LAB 250154
7 XBRL PRESENTATION FILE bvxv-20230630_pre.xml EX-101.PRE 109520
29 EXTRACTED XBRL INSTANCE DOCUMENT ea183829-6ka2_biondvax_htm.xml XML 141089
Mailing Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000
Business Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K/A | Act: 34 | File No.: 001-37353 | Film No.: 231184152
SIC: 2836 Biological Products, (No Diagnostic Substances)